Endonovo Therapeutics, Inc. (ENDV)

Endonovo Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Net Income	-4.4	-18.47	-3.1	-0.4	-17.31	-6.44
Depreciation & Amortization	0.65	0.65	0.65	0.65	0.65	0.65
Other Amortization	0.03	0.11	0.14	0.23	2.24	3.56
Stock-Based Compensation	1	1.36	0.1	0.46	0.19	0.63
Provision & Write-off of Bad Debts	0	0	-	-	-	-
Other Operating Activities	0.53	13.67	0.01	-3.57	10.07	-2.16
Change in Accounts Receivable	-	-	-0	0.02	-0.02	-0
Change in Accounts Payable	0.02	0.27	-0.04	0.09	0.44	0.06
Change in Other Net Operating Assets	1.55	1.74	1.27	1.77	1.2	0.82
Operating Cash Flow	-0.63	-0.68	-0.99	-0.74	-2.54	-2.88
Capital Expenditures	-	-	-	-	-0	-0.01
Investing Cash Flow	-	-	-	-	-0	-0.01
Short-Term Debt Issued	-	-	-	-	-	0.07
Long-Term Debt Issued	-	0.47	0.95	0.61	2	2.84
Total Debt Issued	0.26	0.47	0.95	0.61	2	2.9
Short-Term Debt Repaid	-	-0.01	-0.02	-0.02	-0.11	-0.09
Long-Term Debt Repaid	-	-	-	-	-0.13	-0.56
Total Debt Repaid	-0.05	-0.01	-0.02	-0.02	-0.24	-0.65
Net Debt Issued (Repaid)	0.21	0.45	0.93	0.59	1.76	2.25
Issuance of Common Stock	0.4	0.14	0.13	0.1	0.17	0.79
Financing Cash Flow	0.61	0.59	1.06	0.74	2.18	3.18
Net Cash Flow	-0.02	-0.09	0.07	-0.01	-0.36	0.29
Free Cash Flow	-0.63	-0.68	-0.99	-0.74	-2.54	-2.89
Free Cash Flow Margin	-246.32%	-501.52%	-1349.54%	-447.29%	-820.08%	-3468.29%
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.06	-3.65	-7.97
Cash Interest Paid	-	-	-	0.03	0.02	0.25
Levered Free Cash Flow	2.15	14.95	-0.74	-6.53	4.19	-2.04
Unlevered Free Cash Flow	2.88	15.66	-0.3	-5.46	5.95	-2.25
Change in Net Working Capital	-2.87	-15.7	-0.35	4.75	-7.29	1.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.